Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer
Open Access
- 31 October 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (21), 6822-6830
- https://doi.org/10.1158/1078-0432.ccr-11-1151
Abstract
Purpose: AS1402 is a humanized immunoglobulin G1 antibody that targets the aberrantly glycosylated antigen MUC1, which is overexpressed in 90% of breast tumors and contributes to estrogen-mediated growth and survival of breast cancer cells in vitro by modulating estrogen receptor (ER) activity. Aromatase inhibitors have been reported to enhance antibody-dependent cell-mediated cytotoxicity elicited by antibodies in vitro. We compared the outcomes of patients with breast cancer treated with letrozole with or without AS1402.Keywords
This publication has 24 references indexed in Scilit:
- Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancerBritish Journal of Cancer, 2010
- Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancerBreast Cancer Research, 2009
- MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatmentProceedings of the National Academy of Sciences of the United States of America, 2009
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2008
- A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related EffectsThe Oncologist, 2007
- Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysisJNCI Journal of the National Cancer Institute, 2006
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2003
- Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patientsInternational Journal of Cancer, 2001
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patientsBreast Cancer Research and Treatment, 1985